SkinBioTherapeutics has appointed Stuart Ashman as an executive director, effective from April 18. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. O’Neill will continue to drive the science and the ongoing commercial discussions she has initiated.
Ashman brings over two decades of commercial healthcare experience, primarily in the medical devices industry, having held senior-level positions in a range of large public and smaller private companies.
Since 2014, Ashman has served as CEO of Onbone, a Finnish private equity-backed medical device company. In this role, he established a global sales force and distribution network and built a multimillion pound business with margins of 80%.
Prior to that, Ashman was President/CEO of Andover Healthcare, a US-based wound management manufacturer and President/CEO of TI Group, a UK-based medical/engineering company where he grew revenues from $19 million to $88m per year.
He also served as Senior VP, Global Sales & Strategic Marketing, BSN Medical (Biersdorf, Smith and Nephew) and was Director of Sales & Marketing at Smith & Nephew Plc, in its Woundcare, Casting & Bandaging division.
Martin Hunt, Non-Executive Chairman of SkinBioTherapeutics, commented: "Stuart’s proven track record with both SMEs and larger public companies in Europe and the US will be essential in driving the company forward as we progress towards commercialisation of our first product.
Cath, who has played a pivotal role as CEO, from discovering the technology to founding the Company and leading it through the IPO will continue to lead the science.”
